MedTrace Logo

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

NCT06672536 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2025-09-04

No results posted yet for this study

Summary

Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.

Conditions

Interventions

DRUG

SCT520FF

SCT520FF dose level 1，IVI

DRUG

SCT520FF

SCT520FF dose level 2，IVI

DRUG

SCT520FF

SCT520FF dose level 3，IVI

DRUG

EYLEA 2 MG

EYLEA 2 MG,IVI,injection once every 4 weeks,during the study period

Sponsors & Collaborators

  • Tianjin Medical University Eye Hospital

    collaborator OTHER

  • Sinocelltech Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2026-09-23
Completion
2027-01-11

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06672536 on ClinicalTrials.gov